Cytek Biosciences, Inc. CTKB R2K
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -894.3% CAGR over 5 years.
- Trading 28.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTKB Cytek Biosciences, Inc. R2K | 4.19 | - | $541.11M | - | -7.65% | -20.93% | 7.10% | -894.35% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 41.46M | 45.60M | 52.29M | 62.14M | 44.13M |
| Cost of Revenue | 21.30M | 21.73M | 24.74M | 29.26M | 22.88M |
| Gross Profit | 20.16M | 23.87M | 27.55M | 32.88M | 21.25M |
| Operating Expenses | 35.13M | 34.49M | 36.74M | 38.48M | 39.72M |
| Operating Income | -14.97M | -10.62M | -9.19M | -5.59M | -18.46M |
| EBITDA | -8.09M | -3.37M | -4.21M | -1.71M | -14.30M |
| Interest Expense | 291.00K | 414.00K | 494.00K | -725.00K | 262.00K |
| Pretax Income | -11.27M | -6.78M | -7.77M | -4.03M | -17.37M |
| Tax Provision | 136.00K | -1.19M | -2.29M | 40.05M | 1.49M |
| Net Income | -11.40M | -5.58M | -5.48M | -44.08M | -18.87M |
| Diluted EPS | -0.09 | -0.04 | -0.04 | -0.34 | -0.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 164.04M | 193.01M | 200.45M | 201.49M |
| Cost of Revenue | - | 63.06M | 83.59M | 89.35M | 97.03M |
| Gross Profit | - | 100.97M | 109.43M | 111.11M | 104.46M |
| Operating Expenses | - | 102.78M | 137.27M | 131.63M | 144.84M |
| Operating Income | - | -1.80M | -27.84M | -20.52M | -40.38M |
| EBITDA | - | 9.49M | -4.41M | -10.03M | -17.39M |
| Interest Expense | 1.74M | 2.57M | 2.07M | - | 474.00K |
| Pretax Income | - | 1.26M | -15.71M | -5.70M | -29.84M |
| Tax Provision | - | -1.22M | -3.56M | 320.00K | 36.70M |
| Net Income | - | 2.58M | -12.15M | -6.02M | -66.54M |
| Diluted EPS | - | 0.02 | -0.09 | -0.05 | -0.52 |
Compounded Sales Growth
| 5 Years: | 7.10% |
| 1 Year: | 6.50% |
Compounded Profit Growth
| 5 Years: | -894.35% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +51.26% |
| 6 Months: | -28.01% |
| 3 Months: | -6.47% |
| 1 Month: | -5.63% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 519.48M | 494.46M | 499.50M | 461.54M |
| Current Assets | - | 454.02M | 392.06M | 396.45M | 392.00M |
| Cash & Equivalents | - | 296.60M | 167.30M | 98.72M | 90.85M |
| Inventory | - | 48.15M | 60.88M | 43.89M | 48.43M |
| Receivables | - | 48.86M | 55.93M | 60.59M | 62.51M |
| Total Liabilities | - | 93.93M | 101.39M | 103.76M | 119.80M |
| Current Liabilities | - | 49.04M | 56.23M | 67.66M | 77.80M |
| Long Term Debt | - | 2.27M | 1.65M | 1.05M | 525.00K |
| Total Debt | - | 18.09M | 14.14M | 17.02M | 23.74M |
| Total Equity | - | 425.30M | 393.06M | 395.74M | 341.74M |
| Shares Outstanding | - | 135.37M | 130.71M | 129.21M | 128.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.23M | 5.28M | 25.38M | -4.69M |
| Investing Cash Flow | - | -55.91M | -93.89M | -82.97M | 10.12M |
| Financing Cash Flow | - | 5.51M | -41.81M | -15.82M | -13.43M |
| Capital Expenditure | - | -9.87M | -4.83M | -3.73M | -4.19M |
| Free Cash Flow | - | -22.10M | 454.00K | 21.65M | -8.88M |
| Net Change in Cash | - | -62.63M | -130.43M | -73.42M | -8.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 61.6% | 56.7% | 55.4% | 51.8% |
| Operating Margin % | - | -1.1% | -14.4% | -10.2% | -20.0% |
| Net Margin % | - | 1.6% | -6.3% | -3.0% | -33.0% |
| ROE % | - | 0.6% | -3.1% | -1.5% | -19.5% |
| ROCE % | - | -0.4% | -6.4% | -4.8% | -10.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.17% | 17.01M | $71.26M |
| 2 | Topline Capital Management, LLC | 5.47% | 7.06M | $29.60M |
| 3 | HHLR Advisors, LTD | 5.15% | 6.66M | $27.89M |
| 4 | Millennium Management Llc | 4.87% | 6.29M | $26.36M |
| 5 | Boston Partners | 4.49% | 5.80M | $24.31M |
| 6 | Vanguard Capital Management LLC | 3.69% | 4.76M | $19.96M |
| 7 | State Street Corporation | 3.19% | 4.12M | $17.28M |
| 8 | Geode Capital Management, LLC | 2.19% | 2.83M | $11.87M |
| 9 | Dimensional Fund Advisors LP | 2.06% | 2.66M | $11.16M |
| 10 | Goldman Sachs Group Inc | 1.82% | 2.34M | $9.82M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTKB